Company Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
17.48 USD -0.29% Intraday chart for Catalyst Biosciences -1.85% +127.92%

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Number of employees: 7

Company contact information

Catalyst Biosciences, Inc.

12730 High Bluff Drive Suite 250

92130, San Diego

+650 871 0761

http://www.catalystbiosciences.com
address Catalyst Biosciences(CBIO)

Sector

This company's sector is not yet available
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings